Describing Patient With DME, Their Patient Journey and Disease Progression

This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetic Macular Edema

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CorEvitas HQ

Waltham, Massachusetts, 02451, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients ≥18 years, with a DME diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023)

Exclusion criteria

Patients without the information of laterality will be excluded.

Treatment and study plan

Primary outcomes

Change in visual acuity

Time frame: From January 2015 to April 2023
Progression to DME in the fellow eye

Time frame: From January 2015 to April 2023
Initial treatment of DME

Time frame: From January 2015 to April 2023
Central retinal thickness (CRT)

Time frame: From January 2015 to April 2023

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Observational Study on the Management, and Progression of Patients With Diabetic Macula Edema (DME)

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: Aug 1, 2023
Registry last updated: Dec 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed